

1 **Supplementary Material - Diminished neutralization responses towards SARS-CoV-2**
2 **Omicron VoC after mRNA or vector-based COVID-19 vaccinations**

3 Henning Jacobsen^{#,1}, Monika Strengert^{#,2,3}, Henrike Maaß^{*,1}, Mario Alberto Ynga Durand^{*,1}, Barbora
4 Kessel², Manuela Harries², Ulfert Rand¹, Leila Abassi¹, Yeonsu Kim¹, Tatjana Lüddecke¹, Pilar Hernandez²,
5 Julia Ortmann², Jana-Kristin Heise², Stefanie Castell², Daniela Gornyk², Stephan Glöckner², Vanessa
6 Melhorn², Yvonne Kemmling², Berit Lange^{2,5}, Alex Dulovic⁴, Julia Häring⁴, Daniel Junker⁴, Nicole
7 Schneiderhan-Marra⁴, Markus Hoffmann^{6,7}, Stefan Pöhlmann^{6,7}, Gérard Krause^{2,3,5,§}, Luka Cicin-Sain^{1,5,8,§}

8 1 Helmholtz Centre for Infection Research, Department of Viral Immunology, Braunschweig, Germany

9 2 Helmholtz Centre for Infection Research, Department of Epidemiology, Braunschweig, Germany

10 3 TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover
11 Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

12 4 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

13 5 German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

14 6 Deutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany

15 7 Faculty of Biology and Psychology, Georg-August-University Göttingen, Germany

16 8 Centre for Individualized Infection Medicine (CIIM), a joint venture of Helmholtz Centre for Infection
17 Research and Medical School Hannover, Germany

18

19 # (first authors), * (second authors), § (corresponding authors): these authors contributed equally.

20

21 Corresponding authors contact details:

22 Luka Cicin-Sain, Phone number: +49 (0)53161814616, Email address: luka.cicin-sain@helmholtz-hzi.de,

23 Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.

24

25

26 **Supplementary Table S1.** Comorbidities of study participants (NA: not available; CVD: cardiovascular disease
 27

Sample cohort (n)	Comorbidities (n, %)	CVD (n, %)	Lung disease (n, %)	Diabetes (n, %)	Cancer (n, %)	Immuno-suppression (n, %)	Hypertension (n, %)
two-dose BNT162b2 T1* (15)	0:9 (64.3) 1:4 (28.6) 2:1 (7.1) >2: 0 (0) 1 NA	0(0)	1 (7.1)	0 (0)	0 (0)	0 (0)	5 (35.7)
two-dose BNT162b2 T2* (15)	0: 8 (53.3) 1: 5 (33.3) 2: 2 (13.3) >2: 0 (0)	1 (6.7)	1 (6.7)	0 (0)	0 (0)	2 (13.3)	5 (33.4)
two-dose mRNA-1273 (16)	0: 12 (75.0) 1: 4 (25.0) 2: 0 (0) >2: 0 (0)	1 (6.3)	1 (6.3)	0 (0)	1 (6.3)	0 (0)	1 (6.3)
first dose AZD1222, second dose mRNA-1273 (11)	0: 7 (63.6) 1: 3 (27.3) 2: 1 (9.1) >2: 0 (0)	2 (18.2)	0 (0)	0 (0)	0 (0)	0 (0)	3 (27.3)
first dose AZD1222, second dose BNT162b2 (15)	0: 8 (53.3) 1: 3 (20.0) 2: 3 (20.0) >2: 1 (6.7)	1 (6.7)	1 (6.7)	2 (13.3)	1 (6.7)	0 (0)	7 (46.7)
two-dose AZD1222 (14)	0: 7 (50.0) 1: 6 (42.9) 1: 1 (7.1) >2: 0 (0)	0 (0)	0 (0)	2 (14.3)	0 (0)	0 (0)	6 (42.9)
one-dose Ad26.CoV 2.S (11)	0: 7 (63.6) 1: 3 (27.3) 2: 0 (0) >2: 1 (9.1)	1 (9.1)	1 (9.1)	1 (9.1)	0 (0)	1 (9.1)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

28
29
30
31
32

Supplementary Table S2. Amino acid mutations of Spike proteins used for SARS-CoV-2 pseudotype construction compared to the parental strain B.1. Shared mutations among the constructs are highlighted in bold.

B.1.351 (Beta) (EPI_ISL_700428)	B.1.617.2 (Delta) (EPI_ISL_1921353)	B.1.1.529 (Omicron) (EPI_ISL_6640919)
	T19R	
		A67V
		69-70del
D80A		
		T95I
	G142D	G142D
		143-145del
	E156G	
	157-158del	
		N211del/L212I
		Ins214EPE
242-244del		
R246I		
		G339D
		S371L
		S373P
		S375F
K417N		K417N
		N440K
		G446S
	L452R	
		S477N
	T478K	T478K
E484K		E484A
		Q493R
		G496S
		Q498R
N501Y		N501Y
		Y505H
		T547K
D614G	D614G	D614G
		H655Y
		N679K
	P681R	P681H
A701V		
		N764K
		D796Y
		N856K
	D950N	
		Q954H
		N969K
		L981F

33